[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wild-type-transthyretin-related-attramyloidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wild-type-transthyretin-related-attramyloidosis":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100538512",false,"NCT06291805","Phenotyping and Characterization of wtATTR-CM (TRACE 1)","Phenotyping and Characterization of Danish Wild-type Transthyretin Amyloidosis Cardiomyopathy Patients: A Cross-sectional Study","Group 1: wtATTR-CM patients\n\nInclusion Criteria:\n\n* Patients \\> 18 years diagnosed with ATTRwt-CM by:\n* endomyocardial biopsy\n* DPD scintigraphy with Perugini grade 2-3 where variant amyloidosis is ruled out due to genetic testing.\n* Informed oral and written consent\n\nExclusion Criteria:\n\n* AL amyloidosis (light-chain amyloidosis).\n* Myelomatosis\n* Waldenström macroglobulinemia\n\nGroup 2: Control group\n\nInclusion Criteria:\n\n* Patients \\> 18 years\n* Informed oral and written consent\n\nExclusion Criteria:\n\n* Known cardiovascular disease including ischemic heart disease, heart failure, atrial fibrillation, presence of a pacemaker, or malignant hypertension. Well-controlled hypertension is acceptable.\n* Suspicion of cardiac amyloidosis assessed through clinical history, physical examination, ECG, and echocardiography focusing on \"red flags\":\n* Echocardiography with:\n* Myocardial hypertrophy (septum \\>11 mm)\n* Apical sparing in LV-GLS\n* Infiltrative changes in the right ventricle free wall, thickened atrioventricular valves, or thickened atrial septum\n* Symptoms of polyneuropathy\n* Low voltage on ECG or discrepancy between left ventricular thickness and ECG amplitude indicative of low voltage\n* Atrioventricular block (AV block)\n* Bilateral carpal tunnel syndrome\n* Surgery for spinal stenosis\n* Elevated troponin I or NT-pro-BNP",true,"ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","OBSERVATIONAL","Descriptive cross-sectional study on 100 consecutive ATTRwt-CM patients reflecting all NAC stages aiming primarily to investigate ATTRwt-CM patient's quality of life (QoL) measures and their relation to ATTRwt-CM severity. Secondarily aiming to investigate the possibility to measure misTTR and fragTTR in plasma and urine and to detect fragTTR in endomyocardial biopsies from ATTRwt-CM patients. To investigate whether misTTR and fragTTR levels are correlated with ATTRwt-CM severity.",[24,25,26,27],"Transthyretin Amyloidosis","Transthyretin Amyloid Cardiomyopathy","Wild-Type Transthyretin-Related (ATTR)Amyloidosis","Quality of Life","RECRUITING","2025-08-12",{"date":31,"type":32},"2025-08-15","ACTUAL",{"date":34,"type":32},"2024-02-20",{"date":36,"type":20},"2025-12",{"name":38,"class":39},"Steen Hvitfeldt Poulsen","OTHER",""]